Gene therapy for breast cancer. — review of clinical gene therapy trials for breast cancer and mdr1 gene therapy trial in cancer institute hospital

被引：30

作者：

Takahashi S. ^{[1
]}

Ito Y. ^{[1
]}

Hatake K. ^{[1
]}

Sugimoto Y. ^{[2
,3
]}

机构：

[1] Department of Medical Oncology, Cancer Chemotherapy Center and Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-10-6 Ariake, Koto-ku, Tokyo

[2] Department of Gene Therapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research

[3] Department of Chemotherapy, Kyoritsu University of Pharmacy

来源：

Breast Cancer | 2006年 / 13卷 / 1期

关键词：

Adenoviral vector; Breast cancer; Gene therapy; MDRl; Retroviral vector;

D O I：

10.2325/jbcs.13.8

中图分类号：

学科分类号：

摘要：

Gene therapy for advanced breast cancer is anticipated to be a useful therapeutic approach. Strategies in ongoing clinical protocols can be divided into four groups: (1) suppression of oncogenes or transfer of tumor-suppressor genes; (2) enhancement of immunological response; (3) transfer of suicide genes; (4) protection of bone marrow using drug resistance genes. We have started a clinical study of multidrug resistance (MDRl) gene therapy. Advanced breast cancer patients received high dose chemotherapy and autologous peripheral blood stem cell transplantation (PBSCT) withMDRl-transduced hematopoietic cells, and then were treated with docetaxel. Two patients have been treated so far, andin vivo enrichment ofMDRl-transduced cells with docetaxel treatment has been seen. Both patients are in complete remission and had no apparent adverse effects from theMDRl gene transfer. © 2006, The Japanese Breast Cancer Society.

引用

页码：8 / 15

页数：7

共 32 条

[1]

Hortobagyi G.N., Treatment of breast cancer, N Engl J Med, 339, pp. 974-984, (1998)

[2]

Osborne C., Wilson P., Tripathy D., Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications, Oncologist, 9, pp. 361-377, (2004)

[3]

Coles C., Condie A., Chetty U., Steel C.M., Evans H.J., Prosser J., p53 mutations in breast cancer, Cancer Res, 52, pp. 5291-5298, (1992)

[4]

Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, pp. 783-792, (2001)

[5]

Ueno N.T., Bartholomeusz C., Herrmann J.L., Estrov Z., Shao R., Andreeff M., Price J., Paul R.W., Anklesaria P., Yu D., Et al., E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway, Clin Cancer Res, 6, pp. 250-259, (2000)

[6]

Hortobagyi G.N., Ueno N.T., Xia W., Zhang S., Wolf J.K., Putnam J.B., Weiden P.L., Willey J.S., Carey M., Branham D.L., Et al., Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial, J Clin Oncol, 19, pp. 3422-3433, (2001)

[7]

Yoo G.H., Hung M.C., Lopez-Berestein G., LaFollette S., Ensley J.F., Carey M., Batson E., Reynolds T.C., Murray J.L., Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer, Clin Cancer Res, 7, pp. 1237-1245, (2001)

[8]

Arteaga C.L., Holt J.T., Tissue-targeted antisense c-fos retroviral vector inhibits established breast cancer xenografts in nude mice, Cancer Res, 56, pp. 1098-1103, (1996)

[9]

Holt J.T., Arteaga C.B., Robertson D., Moses H.L., Gene therapy for the treatment of metastatic breast cancer by in vivo transduction with breast-targeted retroviral vector expressing antisense c-fos RNA, Hum Gene Ther, 7, pp. 1367-1380, (1996)

[10]

Mhashilkar A.M., Schrock R.D., Hindi M., Liao J., Sieger K., Kourouma F., Zou-Yang X.H., Onishi E., Takh O., Vedvick T.S., Et al., Melanoma differentiation associated gene-7 (mda-7): a novel anti-tumor gene for cancer gene therapy, Mol Med, 7, pp. 271-282, (2001)

← 1 2 3 4 →